Your AI-Trained Oncology Knowledge Connection!
The trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer.
Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.
Pal discussed findings from the SWOG 1500 trial investigating sunitinib versus either cabozantinib, crizotinib, or savolitinib to treat patients with metastatic papillary RCC.
CancerNetwork® spoke with the CEO of Nanobiotix and an assistant professor of Oncology at John Hopkins Medicine to learn more regarding the potential of the radio enhancer NBTXR3.
The hospitalist at Memorial Sloan Kettering Cancer Center discussed what she believes is most important for practicing oncologists to understand about a study of 177Lu-DOTATATE in well-differentiated, high-grade neuroendocrine tumors.
The KEYNOTE-799 study is evaluating pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
The ongoing phase 2 BGBC008 trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI-refractory composite AXL-positive non–small cell lung cancer.
The hospitalist at Memorial Sloan Kettering Cancer Center spoke about the next steps for a study which evaluated patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE.
CancerNetwork® spoke with the CEO of the Union for International Cancer Control to learn more about their efforts in oncology amidst the COVID-19 pandemic, and the work they are doing on World Cancer Day.
The novel search tool uses artificial intelligence to restructure trial information, making it easier for patients and providers to access clinical trial information.
The hospitalist at Memorial Sloan Kettering Cancer Center highlighted important takeaways from a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.
According to trial investigators, the results of the ongoing BFBC008 study point support the continued development of AXL inhibition with bemcentinib in order to extend the efficacy of immunotherapy in biomarker-selected refractory non–small cell lung cancer.
The urologist at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center spoke about the impact of a decline in cancer screening tests being performed during the first wave of the pandemic.
The expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.
The associate professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center indicated that these data provide the first avenue for personalized treatment of small cell lung cancer.
The expert in hematology/oncology discussed the implications of a study which evaluated the use of peptide receptor radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
